We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Lipid-ELISA Improves Detection of Potential PD Biomarker

By LabMedica International staff writers
Posted on 31 Jul 2017
Print article
Image: Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the brain substantia nigra in Parkinson\'s disease (Photo courtesy of Wikimedia).
Image: Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the brain substantia nigra in Parkinson\'s disease (Photo courtesy of Wikimedia).
Researchers have developed a novel diagnostic approach for Parkinson’s Disease (PD), which enabled assaying of total alpha-synuclein in whole blood cells (WBC), cerebrospinal fluid (CSF), and saliva. The new ELISA assay could lead to early diagnosis and improved monitoring of PD progression and patient response to therapy.

Making an accurate diagnosis of PD is particularly difficult in early stages and mild cases. There are currently no standard diagnostic tests other than clinical information provided by the patient and findings of neurological examination. One of the best hopes for improving diagnosis is to develop a reliable test for identifying changes in the severity of the disease, which would also allow drug companies to test potential drugs at higher efficacy.

The new assay was developed by a research team at the Faculty of Medicine of the Hebrew University of Jerusalem (Jerusalem, Israel) under the supervision of Dr. Ronit Sharon. First author and PhD student Suaad Abd-Elhadi was awarded Hebrew U’s Kaye Innovation Award for 2017 in recognition of her especially important role in developing the assay.

The assay detects the protein alpha-synuclein, a potentially important PD biomarker as it is closely associated with tissues where PD can be detected and with the neurological pathways along which the disease progresses, causing its characteristic symptoms. However, ELISA capture of alpha-synuclein using antibodies raises a concern regarding efficacy for the intracellular, unfolded pool of alpha-synuclein. An alternative to antibodies is capture by membrane lipids based on utilizing the biochemical property of alpha-synuclein to specifically bind membrane lipids and to acquire a characteristic structure following binding.

They determined alpha-synuclein levels in human samples using immobilized lipids for alpha-synuclein capture. Lipids used consisted of phosphatidyl inositol (PI), phosphatidyl serine (PS), and phosphatidyl ethanolamine (PE). Addition of mono-sialoganglioside to the immobilized lipids improved the system. Following capture, the lipid-bound alpha-synuclein was detected using an anti- alpha-synuclein antibody.

The development of a simple and highly sensitive diagnostic tool that can detect PD biomarkers could lead to a minimally invasive and cost-effective way to improve the lives of Parkinson’s patients. Toward this end, the researchers have recently demonstrated a proof-of-concept to the high potential of their lipid-ELISA assay in differentiating healthy and Parkinson’s affected subjects. They are now in the process of analyzing a large cohort as part of a clinical study, including patients with moderate and severe PD. The Hebrew University has signed an agreement with Integra Holdings for further development.

The related study, Abd-Elhadi S by et al, was published November 2016 in the journal Analytical and Bioanalytical Chemistry.

Related Links:
Hebrew University of Jerusalem

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The BIOFIRE® SPOTFIRE® R/ST Panel has received dual 510(k) clearance and CLIA-waiver approval (Photo courtesy of bioMérieux)

Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms

The COVID-19 pandemic has demonstrated the need for healthcare professionals to have diagnostic tests available as close as possible to the patient, providing actionable results quickly.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The RedDrop One blood collection device has received 510(k) clearance from the U.S. FDA for prescription use (Photo courtesy of RedDrop Dx)

Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy

The discomfort associated with traditional blood draws leads to a significant issue: approximately 30% of diagnostic tests prescribed by physicians are never completed by patients. This avoidance is often... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.